Reprogramming Which Peptides Melanoma Cells Display to Make Them More Visible to the Immune System

Researchers treated A375 melanoma cells with a potent ERAP1 inhibitor and analyzed the presented MHC class I peptide repertoire. MHC-I molecules were isolated from treated and untreated cells, bound peptides were eluted, and identified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Peptide length distributions, binding motifs, and predicted MHC-I binding affinities were compared between treated and control conditions.

Immune checkpoint inhibitors (like pembrolizumab and nivolumab) have revolutionized cancer treatment, but many patients don't respond because their tumors don't present enough recognizable peptide targets. This study introduces a fundamentally different approach: rather than boosting the immune response, manipulate what the cancer cells display on their surface to make them more immunogenic. If ERAP1 inhibitors can be developed into drugs, they could complement existing immunotherapies by making unresponsive tumors visible to the immune system.

The immunopeptidome — the collection of peptides displayed on cell surfaces for immune surveillance — is a rapidly growing area of cancer research. This study demonstrates that the peptide processing machinery can be pharmacologically manipulated to enhance tumor immunogenicity. This concept of 'editing' the immunopeptidome represents an emerging therapeutic strategy that could synergize with checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies by ensuring cancer cells display better targets for immune attack.

This study was conducted entirely in cell culture using a single melanoma cell line (A375). Whether ERAP1 inhibition would enhance anti-tumor immune responses in living organisms was not tested. The peptide changes observed in vitro may differ from those occurring in the complex tumor microenvironment. The ERAP1 inhibitor's selectivity, pharmacokinetics, and potential off-target effects on normal cells (which also use ERAP1 for peptide processing) were not addressed. Whether the altered peptides would actually be recognized by patient T cells remains unknown.